{"gene":"LGALS9","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2005,"finding":"Galectin-9 (LGALS9) was identified as the ligand for the Tim-3 (TIM-3) receptor on Th1 cells. Galectin-9 binding to Tim-3 induced intracellular calcium flux, cell aggregation, and apoptotic death of Th1 cells in a Tim-3-dependent manner in vitro; in vivo administration selectively depleted IFN-γ-producing cells and suppressed Th1-mediated autoimmunity.","method":"In vitro binding assays, calcium flux measurements, cell death assays with Tim-3-deficient cells; in vivo administration in autoimmune models","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (binding, calcium flux, genetic Tim-3 dependence, in vivo), foundational paper with >1600 citations replicated broadly","pmids":["16286920"],"is_preprint":false},{"year":1997,"finding":"LGALS9 encodes a novel 36-kDa tandem-repeat galectin (galectin-9) with two carbohydrate recognition domains (CRDs) linked by a ~30 amino acid peptide; the protein binds galactosides via affinity chromatography on lactose/galactose resin and is expressed primarily in peripheral blood leukocytes and lymphatic tissues.","method":"cDNA cloning, sequence analysis, recombinant protein expression in CHO cells, lactose/galactose affinity chromatography","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution of galactoside-binding activity with direct affinity purification; >200 citations","pmids":["9045665"],"is_preprint":false},{"year":1998,"finding":"A splice variant of LGALS9 (ecalectin) was identified as a T-cell-derived eosinophil chemoattractant. Recombinant ecalectin attracted eosinophils in vitro and in vivo in a dose-dependent manner but not neutrophils, lymphocytes, or monocytes, and is secreted despite lacking a hydrophobic signal peptide.","method":"cDNA isolation from T-cell expression library, recombinant protein expression in COS and insect cells, in vitro and in vivo eosinophil chemotaxis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — functional reconstitution in vitro and in vivo with recombinant protein, >250 citations","pmids":["9642261"],"is_preprint":false},{"year":2003,"finding":"Galectin-9 induces apoptosis via the calcium-calpain-caspase-1 pathway. Gal-9-induced apoptosis of T-cell lines requires beta-galactoside binding (blocked by lactose but not sucrose), induces intracellular Ca2+ influx, and is suppressed by a pan-caspase inhibitor, a caspase-1 inhibitor (Z-YVAD-FMK), a calpain inhibitor (Z-LLY-FMK), the Ca2+ chelator BAPTA-AM, or an IP3 inhibitor; caspase-8, -9, and -10 inhibitors had no effect.","method":"Cell death assays with pharmacological inhibitors (caspase, calpain, calcium), calcium flux measurements, lactose competition","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal pharmacological dissections of the pathway, >245 citations","pmids":["12646627"],"is_preprint":false},{"year":2006,"finding":"EBV-infected NPC cells release exosomes containing galectin-9 (LGALS9); exosomal galectin-9 retains Tim-3-binding capacity and has T-cell inhibitory activity, providing a mechanism for immune escape.","method":"Differential centrifugation, immunomagnetic bead purification, Western blotting, T-cell proliferation inhibition assays with anti-Tim-3 and anti-galectin-9 blocking antibodies","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 — exosome isolation with functional validation using blocking antibodies; single lab","pmids":["17156439"],"is_preprint":false},{"year":2008,"finding":"Galectin-9-containing exosomes released by EBV-infected NPC cells circulate in patient plasma, are protected from proteolytic cleavage when encapsulated, retain Tim-3-binding capacity, and induce apoptosis in EBV-specific CD4+ T cells; this effect is blocked by anti-Tim-3 and anti-galectin-9 antibodies.","method":"Exosome isolation from patient plasma and xenograft mouse plasma, T-cell apoptosis assays, antibody blockade experiments","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — in vivo detection plus functional blockade, validated in patient samples and mouse model; >355 citations","pmids":["19005181"],"is_preprint":false},{"year":2010,"finding":"The Tim-3/galectin-9 signaling pathway promotes expansion of CD11b+Ly-6G+ granulocytic myeloid-derived suppressor cells (MDSCs) to suppress Th1 immunity. Transgenic overexpression of Tim-3 on T cells or overexpression of galectin-9 both increase MDSCs; loss of Tim-3 restores normal MDSC levels in Gal-9 transgenic mice, establishing genetic epistasis in this pathway.","method":"Transgenic mouse models (Tim-3 OE, Gal-9 OE), Tim-3 knockout cross, flow cytometry, tumor growth assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis confirmed by double-mutant rescue, >239 citations","pmids":["20574007"],"is_preprint":false},{"year":2011,"finding":"Galectin-9 binds cell surface protein disulfide isomerase (PDI) on Th2 cells, increasing PDI retention on the plasma membrane and altering the redox environment at the cell surface; this galectin-9/PDI interaction enhances T-cell migration through extracellular matrix via β3 integrins and potentiates HIV infection of T cells.","method":"Cell surface binding assays, PDI retention measurements, T-cell migration assays, HIV infection assays; galectin-PDI interaction characterized on Th2 vs. Th1 cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — identification of PDI as a binding partner with functional consequences (migration and HIV), multiple orthogonal readouts; >200 citations","pmids":["21670307"],"is_preprint":false},{"year":2012,"finding":"Tim-3 functions as an inducible human NK-cell co-receptor for galectin-9 (LGALS9) that enhances IFN-γ production. Tim-3 overexpression in NK92 cells markedly increased IFN-γ in response to soluble Gal-9 or Gal-9-expressing tumor cells; Tim-3 cross-linking activated ERK and caused IκBα degradation; Tim-3 blockade significantly decreased IFN-γ production.","method":"NK cell line overexpression, primary NK cell assays with blocking antibodies, Tim-3 cross-linking, Western blotting (ERK, IκBα), IFN-γ ELISA","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — functional gain-of-function and antibody blockade with defined signaling readouts; >315 citations","pmids":["22323453"],"is_preprint":false},{"year":2012,"finding":"In HBV-associated hepatocellular carcinoma (HCC), galectin-9 is expressed at highest levels on Kupffer cells in tumor islets; IFN-γ from tumor-infiltrating T cells stimulates galectin-9 expression on antigen-presenting cells; the Tim-3/galectin-9 pathway drives T-cell replicative senescence; blockade of this pathway restores T-cell proliferation and effector cytokine production.","method":"Immunofluorescence, flow cytometry, IFN-γ stimulation assays, Tim-3/galectin-9 pathway blockade with antibodies, T-cell functional assays","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, functional rescue by pathway blockade, >414 citations","pmids":["22505239"],"is_preprint":false},{"year":2013,"finding":"Endothelial cells express five LGALS9 splice variants (including two novel ones), with splicing confined to exons 5, 6, and 10. The dominant variant galectin-9Δ5, when overexpressed intracellularly, slightly increased endothelial proliferation; recombinant galectin-9Δ5 dose-dependently inhibited endothelial proliferation and migration and had a small inhibitory effect on angiogenesis in vivo.","method":"RT-PCR splice variant identification, HMEC transfection, recombinant protein treatment, proliferation and migration assays, in vivo angiogenesis model","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional assays with recombinant protein and overexpression, but context-dependent results; single lab","pmids":["24333696"],"is_preprint":false},{"year":2013,"finding":"LGALS9 D5 isoform (galectin-9Δ5) expressed in mouse and human decidua suppresses IFN-γ production by decidual natural killer cells; Lgals9 splice variant expression is differentially regulated during gestation; decreased Lgals9 D5/10 expression is associated with spontaneous abortion.","method":"Real-time PCR, immunohistochemistry, mouse gestation model, decidual NK cell functional assays","journal":"Biology of reproduction","confidence":"Medium","confidence_rationale":"Tier 3 — functional suppression assay with specific isoform; single lab","pmids":["23242525"],"is_preprint":false},{"year":2015,"finding":"Recombinant LGALS9 (rLGALS9) is selectively cytotoxic to KRAS-mutant colorectal cancer cells. Upon treatment, rLGALS9 internalizes via early and late endosomes, accumulates in lysosomes, and acts as a lysosomal inhibitor blocking autophagosome-lysosome fusion, leading to autophagosome accumulation, lysosomal swelling, and cell death ('frustrated autophagy'). This activity depends on elevated basal autophagic flux in KRAS-mutant cells and does not occur in BRAF-mutant CRC.","method":"Confocal microscopy (endosomal/lysosomal trafficking), autophagy flux assays, cell death assays in isogenic KRAS/BRAF mutant panels, recombinant protein treatment","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 — imaging-based mechanistic dissection with defined genetic context and multiple readouts; single lab","pmids":["26086204"],"is_preprint":false},{"year":2015,"finding":"TIM-3 and galectin-9 (LGALS9) form an autocrine stimulatory loop in human acute myeloid leukemia stem cells (LSCs). TIM-3 is expressed on LSCs but not normal HSCs; Gal-9/TIM-3 signaling co-activates NF-κB and β-catenin pathways to drive LSC self-renewal; neutralization of Gal-9 inhibited xenogeneic reconstitution of human AML in mice.","method":"Flow cytometry, AML xenograft models, neutralizing antibody experiments, NF-κB and β-catenin pathway analysis, serum Gal-9 ELISA","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, in vivo validation, defined downstream signaling; >228 citations","pmids":["26279267"],"is_preprint":false},{"year":2017,"finding":"Galectin-9 (LGALS9) is an endogenous ligand for the innate immune receptor Dectin-1 on macrophages in pancreatic ductal adenocarcinoma (PDA). Dectin-1 ligation by galectin-9 drives tolerogenic macrophage programming and adaptive immune suppression; deletion of Clec7a (Dectin-1) or blockade of its downstream signaling was protective against PDA progression.","method":"Ligand-receptor binding assays (mouse and human PDA), Clec7a-knockout mouse models, macrophage polarization assays, CD4+/CD8+ T-cell functional rescue experiments","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — identification of novel receptor-ligand pair with genetic and functional validation in vivo; >307 citations","pmids":["28394331"],"is_preprint":false},{"year":2017,"finding":"In AML cells, latrophilin-1 activation drives a PKC- and mTOR-dependent pathway that increases translation and exocytosis of both TIM-3 and galectin-9. TIM-3 participates in galectin-9 secretion and is also released as soluble TIM-3; soluble TIM-3 prevents IL-2 secretion; galectin-9 impairs NK-cell anti-cancer activity.","method":"Latrophilin-1 activation, pharmacological inhibition of PKC/mTOR, Western blotting, ELISA, ex vivo validation with primary AML patient samples","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway dissection with inhibitors, validated in primary patient samples; single lab","pmids":["28750861"],"is_preprint":false},{"year":2020,"finding":"GBM-derived exosomal LGALS9 in cerebrospinal fluid binds TIM-3 on dendritic cells, inhibiting antigen recognition, processing, and presentation, thereby suppressing cytotoxic T-cell-mediated antitumor immunity; blocking exosomal LGALS9 secretion restored durable DC tumor-antigen-presenting activity and antitumor immunity in mice.","method":"CSF exosome proteomics, DC functional assays, TIM-3 binding assays, exosomal LGALS9 knockdown in vivo mouse model, T-cell cytotoxicity assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic in vitro and in vivo validation with specific knockdown; single lab","pmids":["33093453"],"is_preprint":false},{"year":2021,"finding":"Galectin-9 (LGALS9) interacts directly with PD-1 in addition to TIM-3. PD-1 binding to galectin-9 attenuates Gal-9/TIM-3-induced T-cell death, thereby promoting persistence of PD-1+TIM-3+ exhausted T cells. Gal-9 expression and secretion are induced by IFN-β and IFN-γ.","method":"Co-IP and direct binding assays (PD-1 and galectin-9), T-cell death assays with PD-1-expressing and PD-1-deficient cells, IFN stimulation experiments, anti-Gal-9 therapy in tumor models","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding of new receptor (PD-1) confirmed, mechanistic rescue experiment, multiple functional readouts; >509 citations","pmids":["33547304"],"is_preprint":false},{"year":2021,"finding":"Lgals9 deficiency in mice protected against diet-induced obesity, associated with reduced epididymal and mesenteric fat and improved glucose tolerance. Bone marrow transplant experiments demonstrated the effect is non-hematopoietic cell-intrinsic. Gal-9 physically binds peroxiredoxin-2 (PRDX2) in a sugar-chain-independent manner; Gal-9 knockdown in 3T3-L1 adipocytes shifts PRDX2 from its oxidized dimer to reduced monomer form under H2O2-induced oxidative stress.","method":"Lgals9 knockout mice, HFHS diet model, bone marrow transplantation, nanoLC-MS/MS, co-immunoprecipitation, pull-down assay, PRDX2 redox state analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — MS identification of PRDX2 binding confirmed by Co-IP and pull-down with functional redox readout; single lab","pmids":["33727589"],"is_preprint":false},{"year":2021,"finding":"LGALS9 transcription in human endometrial stromal cells is upregulated by the transcription factor HAND2 and downregulated by FOXO1. Phosphorylation of FOXO1 prevents its DNA binding and thus relieves FOXO1-mediated suppression of LGALS9 transcription; steroid hormones regulate LGALS9 expression through modulation of HAND2 expression and FOXO1 phosphorylation status.","method":"Luciferase reporter assays for LGALS9 promoter activity, HAND2/FOXO1 overexpression and knockdown, steroid hormone treatment, RT-qPCR, FOXO1 phosphorylation analysis","journal":"Molecular human reproduction","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay with transcription factor identity established, phosphorylation mechanism defined; single lab","pmids":["34581822"],"is_preprint":false},{"year":2020,"finding":"Histone H3K9 and H3K14 acetylation at the LGALS9 promoter correlates with and regulates LGALS9 mRNA levels in cervical cancer cells; CpG methylation of the LGALS9 promoter does not explain differences in expression between tumoral and non-tumoral cells.","method":"Chromatin immunoprecipitation (ChIP) for H3K9ac and H3K14ac, bisulfite sequencing for CpG methylation, RT-PCR for splice variant identification","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP establishes direct epigenetic mark at promoter linked to expression; single lab","pmids":["32902187"],"is_preprint":false},{"year":2024,"finding":"LGALS9 promotes inflammation in osteoarthritis by activating JNK and ERK1/2 signaling pathways in chondrocytes; LGALS9 knockdown (RNAi and lentivirus) attenuated inflammatory responses in vitro and in vivo OA models.","method":"RNAi knockdown, lentiviral overexpression/knockdown, in vitro and in vivo OA models, qRT-PCR, Western blotting for p-JNK and p-ERK1/2, immunofluorescence, safranin staining","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function and gain-of-function with defined signaling pathway readouts in vivo and in vitro; single lab","pmids":["39278441"],"is_preprint":false},{"year":2025,"finding":"Macrophage-derived LGALS9 interacts with the receptor P4HB (beta-subunit of prolyl 4-hydroxylase) on gastric cancer epithelial cells, activating P4HB to enhance tumor cell proliferation, epithelial-mesenchymal transition, and lipid metabolism; pharmacological P4HB inhibition reversed these effects.","method":"Single-cell RNA sequencing, ligand-receptor interaction analysis, functional proliferation and EMT assays, pharmacological inhibition of P4HB","journal":"Journal of cellular and molecular medicine","confidence":"Low","confidence_rationale":"Tier 3 — receptor-ligand interaction inferred from scRNA-seq with limited biochemical validation; single lab, no replication","pmids":["40534096"],"is_preprint":false},{"year":2025,"finding":"In early-stage endometrial cancer, tumor cell CD47 stimulates macrophage HCK kinase, driving macrophage secretion of LGALS9, IL-10, and TGF-β1; macrophage-derived LGALS9 in turn signals back through CD47 on tumor cells to reinforce proliferation, establishing a CD47–HCK–LGALS9 positive feedback loop. ERRγ was identified as an upstream transcriptional regulator of CD47 suppressed by progesterone.","method":"scRNA-seq, spatial transcriptomics, multiplex immunofluorescence, CCK-8/flow cytometry proliferation assays, GST pull-down mass spectrometry, CUT&Tag, organoid-macrophage co-culture, CD47 inhibition/overexpression","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 — multi-modal validation including GST pull-down, organoid model, and CUT&Tag; single lab","pmids":["41437376"],"is_preprint":false},{"year":2025,"finding":"Recombinant Lgals9 promotes macrophage polarization toward the M2b phenotype in a cardiac transplant context at appropriate concentrations, as validated by flow cytometry and ELISA.","method":"Single-cell RNA sequencing, RT-qPCR, Western blotting, flow cytometry, ELISA, recombinant Lgals9 treatment of macrophages in vitro","journal":"Journal of leukocyte biology","confidence":"Low","confidence_rationale":"Tier 3 — single in vitro recombinant protein treatment experiment; single lab, no mechanistic pathway identified","pmids":["39835675"],"is_preprint":false},{"year":2025,"finding":"Intratumoral cell-associated (non-secreted) LGALS9 suppresses cytotoxic T lymphocyte activation in nasopharyngeal carcinoma via a macroautophagy-dependent mechanism.","method":"LGALS9 overexpression in NPC cell lines, autophagy manipulation, CTL activation assays (commentary/brief report citing Kam et al. experimental data)","journal":"Autophagy","confidence":"Low","confidence_rationale":"Tier 3 — commentary describing experimental findings from cited primary paper; limited direct experimental detail in abstract","pmids":["40698512"],"is_preprint":false},{"year":2025,"finding":"Rhamnose binds to CEACAM1 at sites V39, D40, and T101, promoting CEACAM1–LGALS9 interaction in macrophages, which increases DUSP1 protein levels, inhibits p38 phosphorylation, and attenuates LPS-induced proinflammatory cytokine expression.","method":"LPS-induced endotoxic mouse model, molecular docking, in vitro macrophage binding assays, CEACAM1-LGALS9 co-immunoprecipitation, Western blotting for DUSP1 and p-p38, cytokine ELISA","journal":"Acta biochimica et biophysica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP confirmed CEACAM1-LGALS9 interaction with defined downstream signaling in vitro and in vivo; single lab","pmids":["40708539"],"is_preprint":false},{"year":2025,"finding":"In keratoconus, LGALS9-positive corneal epithelial cells interact with COMP-positive and CD44-positive stromal cells through LGALS9-CD44 and thrombospondin signaling pathways, promoting extracellular matrix remodeling and a pro-fibrotic/pro-inflammatory network; LGALS9 upregulation in keratoconus corneal epithelium was validated by immunofluorescence and Western blot.","method":"Single-cell RNA sequencing, intercellular communication analysis, immunofluorescence, Western blotting in patient keratoconus vs. control corneal tissue","journal":"International journal of biological macromolecules","confidence":"Low","confidence_rationale":"Tier 3 — interaction inferred from scRNA-seq with validation limited to expression-level confirmation; single lab","pmids":["41022233"],"is_preprint":false}],"current_model":"LGALS9 encodes galectin-9, a secreted tandem-repeat β-galactoside-binding lectin that functions as the canonical ligand for the TIM-3 immune checkpoint receptor, inducing Th1 cell death via a Ca2+-calpain-caspase-1 cascade and suppressing antitumor immunity through exosomal delivery to dendritic cells and direct TIM-3 signaling; it additionally binds PD-1 (attenuating Gal-9/TIM-3 killing to sustain exhausted T cells), Dectin-1 on macrophages (driving tolerogenic programming in pancreatic cancer), and cell-surface PDI (altering redox status and β3-integrin-mediated migration on Th2 cells), while intracellularly acting as a lysosomal inhibitor that blocks autophagosome-lysosome fusion to trigger 'frustrated autophagy' selectively in KRAS-mutant cancer cells, and its transcription is regulated by HAND2 (activating) and FOXO1 (repressing) with histone H3K9/H3K14 acetylation as an additional epigenetic control layer."},"narrative":{"teleology":[{"year":1997,"claim":"Molecular cloning established that LGALS9 encodes a tandem-repeat galectin with two carbohydrate-recognition domains capable of β-galactoside binding, defining the protein's fundamental biochemical identity.","evidence":"cDNA cloning, recombinant expression in CHO cells, lactose/galactose affinity chromatography","pmids":["9045665"],"confidence":"High","gaps":["Three-dimensional structure of full-length tandem-repeat protein not resolved","Relative affinities of N- and C-terminal CRDs for complex glycans not defined"]},{"year":1998,"claim":"Discovery that a galectin-9 splice variant (ecalectin) acts as a selective eosinophil chemoattractant revealed that galectin-9 has direct leukocyte-recruiting activity independent of its later-identified Tim-3 pathway.","evidence":"Recombinant ecalectin in COS/insect cells, in vitro and in vivo eosinophil chemotaxis assays","pmids":["9642261"],"confidence":"High","gaps":["Receptor mediating eosinophil chemotaxis not identified","Mechanism of non-classical secretion not established"]},{"year":2003,"claim":"Pharmacological dissection showed galectin-9 induces T-cell apoptosis through a Ca²⁺–calpain–caspase-1 pathway, distinguishing this death mechanism from classical caspase-8/9-dependent apoptosis.","evidence":"T-cell death assays with selective caspase, calpain, and calcium inhibitors; lactose competition","pmids":["12646627"],"confidence":"High","gaps":["Direct calpain substrates downstream of galectin-9 not identified","Tim-3 dependence not yet tested (predates Tim-3 identification as the receptor)"]},{"year":2005,"claim":"Identification of galectin-9 as the endogenous ligand for TIM-3 on Th1 cells unified the eosinophil/apoptosis activities under a receptor-mediated framework and established the TIM-3/galectin-9 axis as an immune checkpoint.","evidence":"In vitro binding, calcium flux, Tim-3-deficient cell controls, in vivo depletion of IFN-γ+ cells in autoimmune models","pmids":["16286920"],"confidence":"High","gaps":["Whether Tim-3 is the sole apoptosis-inducing receptor or other receptors contribute remained unclear","Structural basis of galectin-9/Tim-3 interaction not determined"]},{"year":2006,"claim":"Demonstration that EBV-infected tumor cells package galectin-9 into exosomes that retain Tim-3-binding and T-cell-inhibitory capacity revealed a paracrine immune-evasion mechanism, later confirmed in patient plasma and extended to glioblastoma-derived CSF exosomes.","evidence":"Exosome purification from NPC cell lines and patient plasma, antibody blockade, DC/T-cell functional assays, in vivo knockdown (GBM model)","pmids":["17156439","19005181","33093453"],"confidence":"High","gaps":["Sorting mechanism for galectin-9 loading into exosomes not defined","Relative contribution of exosomal versus soluble galectin-9 to immune suppression in vivo not quantified"]},{"year":2010,"claim":"Genetic epistasis experiments using Tim-3-overexpressing and Gal-9-overexpressing transgenic mice showed that the Tim-3/galectin-9 axis expands granulocytic MDSCs, broadening the pathway's immunosuppressive scope beyond direct T-cell killing.","evidence":"Tim-3-OE × Gal-9-OE double-transgenic and Tim-3-KO rescue crosses, flow cytometry, tumor models","pmids":["20574007"],"confidence":"High","gaps":["Signaling cascade from Tim-3 in myeloid cells driving MDSC expansion not mapped","Whether MDSC expansion is cell-intrinsic or indirect not resolved"]},{"year":2011,"claim":"Identification of cell-surface protein disulfide isomerase (PDI) as a galectin-9 receptor on Th2 cells revealed a Tim-3-independent pathway linking galectin-9 to redox regulation, β3-integrin-mediated migration, and HIV entry.","evidence":"Surface binding assays, PDI retention measurements, migration and HIV infection assays comparing Th1/Th2 cells","pmids":["21670307"],"confidence":"High","gaps":["Glycan moieties on PDI mediating galectin-9 binding not characterized","Relative physiological importance of PDI versus Tim-3 pathway on Th2 cells unknown"]},{"year":2012,"claim":"Tim-3 was shown to function as a co-stimulatory receptor for galectin-9 on NK cells (activating ERK and NF-κB to enhance IFN-γ), contrasting with its pro-apoptotic role on Th1 cells and demonstrating cell-type-specific signaling outcomes.","evidence":"NK92 overexpression, primary NK blocking antibody experiments, Western blotting for ERK and IκBα","pmids":["22323453"],"confidence":"High","gaps":["Molecular basis for opposing outcomes in T cells versus NK cells not explained","Adaptor proteins downstream of Tim-3 in NK cells not identified"]},{"year":2015,"claim":"Two discoveries expanded galectin-9's functional repertoire: an autocrine TIM-3/Gal-9 loop co-activating NF-κB and β-catenin for AML LSC self-renewal, and an intracellular role as a lysosomal inhibitor that blocks autophagosome–lysosome fusion to selectively kill KRAS-mutant CRC cells.","evidence":"AML xenograft models with neutralizing antibody, NF-κB/β-catenin pathway analysis; confocal endosomal/lysosomal trafficking, autophagy flux assays in isogenic KRAS/BRAF panels","pmids":["26279267","26086204"],"confidence":"High","gaps":["Direct lysosomal target of galectin-9 not identified","Whether intracellular Gal-9 and secreted Gal-9 have distinct structural states not known","Mechanism by which KRAS dependency confers selective sensitivity not fully resolved"]},{"year":2017,"claim":"Galectin-9 was identified as an endogenous ligand for the innate receptor Dectin-1 on macrophages, revealing a Tim-3-independent immunosuppressive axis in pancreatic cancer where Dectin-1 ligation drives tolerogenic macrophage polarization.","evidence":"Ligand-receptor binding assays, Clec7a-knockout mice, macrophage polarization and T-cell rescue experiments in PDA models","pmids":["28394331"],"confidence":"High","gaps":["Glycan determinants distinguishing Gal-9 binding to Dectin-1 versus Tim-3 not mapped","Whether Dectin-1/Gal-9 signaling operates in non-pancreatic tumors not tested"]},{"year":2021,"claim":"Discovery that galectin-9 directly binds PD-1 and that PD-1 co-engagement attenuates Tim-3-mediated T-cell death fundamentally reframed the checkpoint: Gal-9 is a multi-receptor hub where PD-1 acts as a protective co-receptor sustaining exhausted T cells.","evidence":"Co-IP and direct binding assays, PD-1-deficient T-cell death comparisons, IFN-β/γ induction experiments, anti-Gal-9 tumor therapy","pmids":["33547304"],"confidence":"High","gaps":["Whether PD-L1 and Gal-9 compete for PD-1 binding not determined","Crystal structure of PD-1/Gal-9 complex not available","Therapeutic implications of dual PD-1 + Gal-9 blockade versus single blockade not fully characterized"]},{"year":2021,"claim":"Transcriptional regulation of LGALS9 was delineated: HAND2 activates and FOXO1 represses the LGALS9 promoter in endometrial stromal cells, with FOXO1 phosphorylation relieving suppression; separately, histone H3K9/H3K14 acetylation at the promoter controls expression in cervical cancer cells.","evidence":"Luciferase reporter assays, HAND2/FOXO1 overexpression/knockdown, ChIP for H3K9ac/H3K14ac, bisulfite sequencing","pmids":["34581822","32902187"],"confidence":"Medium","gaps":["Whether HAND2/FOXO1 regulation operates outside endometrial tissue not tested","Identity of histone acetyltransferases/deacetylases acting at the LGALS9 promoter not determined"]},{"year":2025,"claim":"Recent studies extended galectin-9's receptor repertoire to CEACAM1 on macrophages (increasing DUSP1 and inhibiting p38 to suppress inflammation) and identified additional signaling contexts including JNK/ERK activation in osteoarthritis chondrocytes and a CD47–HCK–LGALS9 feedback loop in endometrial cancer.","evidence":"Co-IP for CEACAM1–LGALS9, endotoxemia mouse model; RNAi/lentiviral knockdown in OA models; scRNA-seq, organoid–macrophage co-culture, CUT&Tag in endometrial cancer","pmids":["40708539","39278441","41437376"],"confidence":"Medium","gaps":["Direct biochemical binding of galectin-9 to CEACAM1 versus indirect association not fully distinguished","Relative contributions of multiple galectin-9 receptors in any single disease context not integrated","Whether CD47 is a direct galectin-9 receptor or signals indirectly not resolved"]},{"year":null,"claim":"Key unresolved questions include the structural basis of galectin-9's selective engagement with its expanding receptor repertoire (TIM-3, PD-1, Dectin-1, PDI, CEACAM1), the molecular identity of its intracellular lysosomal target mediating autophagy blockade, and the determinants that switch TIM-3/Gal-9 signaling between pro-apoptotic (T cells) and pro-survival (AML LSCs, NK cells) outcomes.","evidence":"","pmids":[],"confidence":"High","gaps":["No co-crystal structure for any galectin-9/receptor complex","Intracellular lysosomal target not identified","Cell-type-specific adaptor proteins downstream of TIM-3 not mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,5,14,17]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,7,14]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,13,17]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,2,5,17]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[4,5,16]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[12]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[12,25]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,3,6,8,9,14,17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,3,5]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,13,17,21]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[12,25]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,5,16]}],"complexes":[],"partners":["HAVCR2","PDCD1","CLEC7A","P4HB","CEACAM1","PRDX2","CD44"],"other_free_text":[]},"mechanistic_narrative":"Galectin-9 is a tandem-repeat β-galactoside-binding lectin that functions as a pleiotropic immunomodulator, shaping adaptive and innate immunity through engagement of multiple cell-surface receptors and an intracellular role in autophagy regulation. Secreted galectin-9 is the canonical ligand for TIM-3, triggering Th1 cell apoptosis via a Ca²⁺–calpain–caspase-1 cascade [PMID:16286920, PMID:12646627], and also binds PD-1, where PD-1 co-engagement attenuates TIM-3-mediated killing and sustains exhausted T-cell persistence [PMID:33547304]; additionally, it ligates Dectin-1 on macrophages to drive tolerogenic programming in pancreatic cancer [PMID:28394331], and binds cell-surface protein disulfide isomerase to modulate Th2 migration and redox status [PMID:21670307]. Tumor-derived exosomal galectin-9 suppresses antitumor immunity by inhibiting dendritic-cell antigen presentation [PMID:33093453, PMID:19005181], while an autocrine TIM-3/galectin-9 loop co-activates NF-κB and β-catenin to promote leukemia stem-cell self-renewal [PMID:26279267]; intracellularly, galectin-9 acts as a lysosomal inhibitor that blocks autophagosome–lysosome fusion, selectively killing KRAS-mutant colorectal cancer cells through frustrated autophagy [PMID:26086204]."},"prefetch_data":{"uniprot":{"accession":"O00182","full_name":"Galectin-9","aliases":["Ecalectin","Tumor antigen HOM-HD-21"],"length_aa":355,"mass_kda":39.5,"function":"Binds galactosides (PubMed:18005988). Has high affinity for the Forssman pentasaccharide (PubMed:18005988). Ligand for HAVCR2/TIM3 (PubMed:16286920). Binding to HAVCR2 induces T-helper type 1 lymphocyte (Th1) death (PubMed:16286920). Also stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth (By similarity). Ligand for P4HB; the interaction retains P4HB at the cell surface of Th2 T-helper cells, increasing disulfide reductase activity at the plasma membrane, altering the plasma membrane redox state and enhancing cell migration (PubMed:21670307). Ligand for CD44; the interaction enhances binding of SMAD3 to the FOXP3 promoter, leading to up-regulation of FOXP3 expression and increased induced regulatory T (iTreg) cell stability and suppressive function (By similarity). Promotes ability of mesenchymal stromal cells to suppress T-cell proliferation (PubMed:23817958). Expands regulatory T-cells and induces cytotoxic T-cell apoptosis following virus infection (PubMed:20209097). Activates ERK1/2 phosphorylation inducing cytokine (IL-6, IL-8, IL-12) and chemokine (CCL2) production in mast and dendritic cells (PubMed:16116184, PubMed:24465902). Inhibits degranulation and induces apoptosis of mast cells (PubMed:24465902). Induces maturation and migration of dendritic cells (PubMed:16116184, PubMed:25754930). Inhibits natural killer (NK) cell function (PubMed:23408620). Can transform NK cell phenotype from peripheral to decidual during pregnancy (PubMed:25578313). Astrocyte derived galectin-9 enhances microglial TNF production (By similarity). May play a role in thymocyte-epithelial interactions relevant to the biology of the thymus. May provide the molecular basis for urate flux across cell membranes, allowing urate that is formed during purine metabolism to efflux from cells and serving as an electrogenic transporter that plays an important role in renal and gastrointestinal urate excretion (By similarity). Highly selective to the anion urate (By similarity) Acts as an eosinophil chemoattractant (PubMed:9642261). It also inhibits angiogenesis (PubMed:24333696). Suppresses IFNG production by natural killer cells (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O00182/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LGALS9","classification":"Not Classified","n_dependent_lines":34,"n_total_lines":1208,"dependency_fraction":0.028145695364238412},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LGALS9","total_profiled":1310},"omim":[{"mim_id":"606652","title":"HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HAVCR2","url":"https://www.omim.org/entry/606652"},{"mim_id":"606096","title":"LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 12; LGALS12","url":"https://www.omim.org/entry/606096"},{"mim_id":"601879","title":"LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 9; LGALS9","url":"https://www.omim.org/entry/601879"},{"mim_id":"153619","title":"LECTIN, GALACTOSIDE-BINDING, SOLUBLE, 3; LGALS3","url":"https://www.omim.org/entry/153619"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":92.9},{"tissue":"stomach 1","ntpm":82.6}],"url":"https://www.proteinatlas.org/search/LGALS9"},"hgnc":{"alias_symbol":["LGALS9A"],"prev_symbol":[]},"alphafold":{"accession":"O00182","domains":[{"cath_id":"2.60.120.200","chopping":"11-149","consensus_level":"high","plddt":97.0732,"start":11,"end":149},{"cath_id":"2.60.120.200","chopping":"228-355","consensus_level":"high","plddt":97.6511,"start":228,"end":355}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00182","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00182-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00182-F1-predicted_aligned_error_v6.png","plddt_mean":84.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LGALS9","jax_strain_url":"https://www.jax.org/strain/search?query=LGALS9"},"sequence":{"accession":"O00182","fasta_url":"https://rest.uniprot.org/uniprotkb/O00182.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00182/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00182"}},"corpus_meta":[{"pmid":"37554219","id":"PMC_37554219","title":"A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9).","date":"2022","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37554219","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33093453","id":"PMC_33093453","title":"Exosomal LGALS9 in the cerebrospinal fluid of glioblastoma patients suppressed dendritic cell antigen presentation and cytotoxic T-cell immunity.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33093453","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31747929","id":"PMC_31747929","title":"Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma.","date":"2019","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/31747929","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24333696","id":"PMC_24333696","title":"Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24333696","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26086204","id":"PMC_26086204","title":"The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/26086204","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23242525","id":"PMC_23242525","title":"Profiling Lgals9 splice variant expression at the fetal-maternal interface: implications in normal and pathological human pregnancy.","date":"2013","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23242525","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29481735","id":"PMC_29481735","title":"Role of Lgals9 Deficiency in Attenuating Nephritis and Arthritis in BALB/c Mice in a Pristane-Induced Lupus Model.","date":"2018","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/29481735","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32902187","id":"PMC_32902187","title":"Histone H3K9 and H3K14 acetylation at the promoter of the LGALS9 gene is associated with mRNA levels in cervical cancer cells.","date":"2020","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/32902187","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31600237","id":"PMC_31600237","title":"Galectin-9 gene (LGALS9) polymorphisms are associated with rheumatoid arthritis in Brazilian patients.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31600237","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34371260","id":"PMC_34371260","title":"Gene polymorphisms of LGALS2, LGALS3 and LGALS9 in patients with rheumatoid arthritis.","date":"2021","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34371260","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26598225","id":"PMC_26598225","title":"Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol.","date":"2015","source":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association","url":"https://pubmed.ncbi.nlm.nih.gov/26598225","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34581822","id":"PMC_34581822","title":"Transcriptional regulation of LGALS9 by HAND2 and FOXO1 in human endometrial stromal cells in women with regular cycles.","date":"2021","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/34581822","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39044269","id":"PMC_39044269","title":"Summary data-based Mendelian randomization and single-cell RNA sequencing analyses identify immune associations with low-level LGALS9 in sepsis.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39044269","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39334929","id":"PMC_39334929","title":"Potential Plasma Proteins (LGALS9, LAMP3, PRSS8 and AGRN) as Predictors of Hospitalisation Risk in COVID-19 Patients.","date":"2024","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39334929","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33727589","id":"PMC_33727589","title":"Lgals9 deficiency ameliorates obesity by modulating redox state of PRDX2.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33727589","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38248876","id":"PMC_38248876","title":"Nicotine Potentially Alters Endothelial Inflammation and Cell Adhesion via LGALS9.","date":"2023","source":"Journal of cardiovascular development and disease","url":"https://pubmed.ncbi.nlm.nih.gov/38248876","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41437376","id":"PMC_41437376","title":"Targeting the CD47-HCK-LGALS9 axis disrupts proliferation-immunosuppression coupling in early-stage endometrial cancer.","date":"2025","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/41437376","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39046608","id":"PMC_39046608","title":"Circulating CD8 + LGALS9 + T Cell Population Exhibiting Low Cytotoxic Characteristics are Decreased in Patients with Systemic Lupus Erythematosus.","date":"2024","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/39046608","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39278441","id":"PMC_39278441","title":"Study on pro-inflammatory effect and mechanism of galectin-9 (LGALS9) in osteoarthritis: Exacerbating inflammatory response by activating JNK and ERK1/2 pathways.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/39278441","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40534096","id":"PMC_40534096","title":"Myeloid-Derived LGALS9-P4HB Immune Interaction Promotes Metastasis in Gastric Cancer Through Enhanced Cell Proliferation and Lipid Metabolism.","date":"2025","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40534096","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39835675","id":"PMC_39835675","title":"Single-cell RNA sequencing revealed the immunophenotypic features of macrophages in cardiac transplants and uncovered Lgals9 promoted their polarization toward the M2b subtype.","date":"2025","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/39835675","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41194934","id":"PMC_41194934","title":"MFSD12 promotes proliferation, metastasis and invasion of hepatocellular carcinoma cells and its potential correlation with HAVCR2/LGALS9 immune checkpoint axis.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41194934","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41171621","id":"PMC_41171621","title":"The LGALS9/miR-491-5p Axis Regulates CD8+ T Cell Function and Inhibits the Progression of Gastric Cancer.","date":"2025","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/41171621","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40698512","id":"PMC_40698512","title":"Autophagy inhibition in LGALS9-overexpressing nasopharyngeal carcinoma unleashes immune response.","date":"2025","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/40698512","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41022233","id":"PMC_41022233","title":"Single-cell RNA sequencing reveals LGALS9+ epithelial and COMP+ stromal cell crosstalk driving keratoconus pathogenesis.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41022233","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40708539","id":"PMC_40708539","title":"Rhamnose alleviates the proinflammatory response during endotoxemia via the CEACAM1/LGALS9-p38 axis.","date":"2025","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/40708539","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.11.19.689365","title":"Proteogenomic profiling of soft tissue leiomyosarcoma reveals distinct molecular subtypes with divergent outcomes and therapeutic vulnerabilities","date":"2025-11-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.19.689365","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.11.20.25337809","title":"Rare case of Pediatric Male Secretory Breast Carcinoma: An Integrative study with Genomic and Transcriptomic analysis","date":"2025-11-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.20.25337809","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.05.24.655902","title":"Adaptive-like NK cell responses to influenza correlate with humoral immunity and are influenced by age and sex","date":"2025-05-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.24.655902","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16286920","id":"PMC_16286920","title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.","date":"2005","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16286920","citation_count":1663,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33547304","id":"PMC_33547304","title":"Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33547304","citation_count":509,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22505239","id":"PMC_22505239","title":"Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.","date":"2012","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22505239","citation_count":414,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19005181","id":"PMC_19005181","title":"Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19005181","citation_count":355,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12761501","id":"PMC_12761501","title":"Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12761501","citation_count":331,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22323453","id":"PMC_22323453","title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22323453","citation_count":315,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28394331","id":"PMC_28394331","title":"Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance.","date":"2017","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28394331","citation_count":307,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9642261","id":"PMC_9642261","title":"Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9642261","citation_count":256,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12646627","id":"PMC_12646627","title":"Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12646627","citation_count":245,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20574007","id":"PMC_20574007","title":"Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20574007","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26279267","id":"PMC_26279267","title":"A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression.","date":"2015","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/26279267","citation_count":228,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9045665","id":"PMC_9045665","title":"Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9045665","citation_count":210,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17156439","id":"PMC_17156439","title":"Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9.","date":"2006","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17156439","citation_count":205,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25037231","id":"PMC_25037231","title":"Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25037231","citation_count":203,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21670307","id":"PMC_21670307","title":"Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21670307","citation_count":201,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28750861","id":"PMC_28750861","title":"The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells.","date":"2017","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/28750861","citation_count":195,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29389859","id":"PMC_29389859","title":"Role of Galectins in Tumors and in Clinical Immunotherapy.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29389859","citation_count":179,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32433612","id":"PMC_32433612","title":"TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32433612","citation_count":176,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16333,"output_tokens":3720,"usd":0.0524},"stage2":{"model":"claude-opus-4-6","input_tokens":7124,"output_tokens":2526,"usd":0.148155},"total_usd":0.531182,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":29718,"output_tokens":7296,"usd":0.099297},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11259,"output_tokens":3917,"usd":0.23133}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"Exosomal LGALS9 secreted by glioblastoma cells binds to the TIM-3 receptor on dendritic cells in cerebrospinal fluid, inhibiting antigen recognition, processing and presentation by DCs, thereby suppressing cytotoxic T-cell-mediated antitumor immune response. Blocking exosomal LGALS9 secretion restored DC antigen-presenting activity and durable antitumor immunity in mice.\",\n      \"method\": \"Proteomic analysis of CSF exosomes, TIM-3 receptor binding assay, DC functional assays, in vivo mouse tumor model with exosomal LGALS9 blockade\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor-ligand interaction identified with functional consequence, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33093453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Recombinant LGALS9 internalizes via early- and late-endosomes into the lysosomal compartment of KRAS-mutant colorectal cancer cells, where it acts as a lysosomal inhibitor blocking autophagosome-lysosome fusion, leading to autophagosome accumulation, lysosomal swelling, and cell death (frustrated autophagy). This antitumor activity was specific to KRAS-mutant CRC with elevated basal autophagic flux and did not occur in BRAF-mutant CRC.\",\n      \"method\": \"Live-cell imaging of endosomal trafficking, autophagy flux assays, lysosomal function assays, genetic comparison of KRAS vs. BRAF mutant cell lines\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined cellular mechanism with multiple orthogonal assays, single lab\",\n      \"pmids\": [\"26086204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Endothelial cells express five LGALS9 splice variants (including two previously unreported), with splicing confined to exons 5, 6 and 10. The dominant splice variant galectin-9Δ5, when applied as recombinant protein, dose-dependently reduced proliferation and migration of endothelial cells in vitro, and induced a modest inhibitory effect on angiogenesis in vivo; intracellular overexpression of galectin-9Δ5 slightly increased proliferation.\",\n      \"method\": \"RT-PCR splice variant characterization, HMEC and HUVEC transfection, recombinant protein treatment assays, in vivo angiogenesis model\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — splice variant identification combined with functional in vitro and in vivo assays, single lab\",\n      \"pmids\": [\"24333696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The LGALS9 D5 isoform suppresses interferon-gamma production by decidual natural killer cells. Lgals9 splice variant expression is differentially regulated during mouse gestation and is deregulated in a mouse model of spontaneous abortion, implicating LGALS9 in fetal-maternal tolerance.\",\n      \"method\": \"Real-time PCR, immunohistochemistry, NK cell functional assay with recombinant isoform\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional isoform effect shown in one assay, limited mechanistic detail\",\n      \"pmids\": [\"23242525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Lgals9 deficiency in mice protected against pristane-induced lupus nephritis, arthritis, and peritoneal lipogranuloma formation. The protection was associated with effects on macrophage activation rather than alteration of T/B cell subset composition or the TLR7-type I interferon pathway, indicating Gal-9 acts through macrophage-dependent mechanisms in lupus pathogenesis.\",\n      \"method\": \"Lgals9 knockout mouse model, pristane-induced lupus model, flow cytometry of immune subsets, cytokine analysis from peritoneal macrophages\",\n      \"journal\": \"Arthritis & rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular phenotype and pathway placement by epistasis, single lab\",\n      \"pmids\": [\"29481735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Gal-9 binds to peroxiredoxin-2 (PRDX2) in a sugar chain-independent manner. In adipocytes, Gal-9 knockdown shifts PRDX2 from its oxidized dimer form to the reduced monomer form under oxidative stress, implicating the Gal-9/PRDX2 interaction in regulation of redox state. Lgals9-deficient mice were resistant to diet-induced obesity with improved glucose tolerance.\",\n      \"method\": \"nanoLC-MS/MS, co-immunoprecipitation, pull-down assay, RNAi knockdown, 3T3-L1 adipocyte oxidative stress assay, Lgals9 knockout mouse fed high-fat diet\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — novel binding partner identified by MS and confirmed by Co-IP/pulldown with functional consequence in vitro, single lab\",\n      \"pmids\": [\"33727589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HAND2 upregulates and FOXO1 downregulates LGALS9 transcription in endometrial stromal cells. Phosphorylation of FOXO1 prevents its DNA binding and thus relieves FOXO1-mediated repression of LGALS9, providing a molecular mechanism for steroid hormone-driven regulation of LGALS9 expression in the endometrium.\",\n      \"method\": \"Luciferase reporter assay of LGALS9 upstream region, transcription factor overexpression/knockdown, phospho-FOXO1 analysis, RT-qPCR\",\n      \"journal\": \"Molecular human reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transcriptional regulation established by reporter assays and phosphorylation analysis, single lab with orthogonal methods\",\n      \"pmids\": [\"34581822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Histone H3K9 and H3K14 acetylation at the LGALS9 promoter correlates with LGALS9 mRNA expression levels in cervical cancer cells, while CpG methylation at the promoter does not show hypermethylation related to low expression, indicating histone acetylation rather than DNA methylation is the primary epigenetic regulator of LGALS9 transcription.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), bisulfite sequencing, RT-qPCR\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — ChIP-based correlation between histone marks and expression, single lab, no functional rescue experiment\",\n      \"pmids\": [\"32902187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LGALS9 exacerbates inflammatory responses in osteoarthritis by activating JNK and ERK1/2 (MAPK) signaling pathways in chondrocytes. RNAi knockdown and lentiviral overexpression of LGALS9 modulated inflammatory markers and pathway activation in in vitro and in vivo OA models.\",\n      \"method\": \"RNAi knockdown, lentiviral overexpression, qRT-PCR, western blot, immunofluorescence, in vivo OA mouse model\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — pathway activation identified by KD/OE with signaling readouts, single lab\",\n      \"pmids\": [\"39278441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In endometrial cancer, macrophage-derived LGALS9 binds to CD47 on epithelial cancer cells, and EC cells engage macrophages through the CD47-HCK axis, driving macrophage secretion of LGALS9, IL-10, and TGF-β1 to create an immunosuppressive microenvironment. Macrophage-derived LGALS9 reinforces EC cell proliferation via CD47, establishing a positive feedback loop (CD47-HCK-LGALS9). ERRγ was identified as an upstream transcriptional regulator of CD47, suppressed by progesterone.\",\n      \"method\": \"GST pull-down mass spectrometry, molecular docking, scRNA-seq, spatial transcriptomics, CUT&Tag for transcription factor identification, organoid-macrophage co-culture, flow cytometry, CCK-8 proliferation assay\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor-ligand interaction validated by pull-down MS and multiple functional assays, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"41437376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Myeloid cell-derived LGALS9 binds to P4HB (prolyl 4-hydroxylase beta subunit) on gastric cancer epithelial cells; P4HB activation by LGALS9 enhances proliferation, epithelial-mesenchymal transition, and lipid metabolism in gastric cancer cells, while pharmacological inhibition of P4HB reverses these effects.\",\n      \"method\": \"Single-cell RNA sequencing, ligand-receptor interaction analysis, functional proliferation and EMT assays, pharmacological P4HB inhibition\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — novel binding partner identified computationally and supported by functional assays, single lab, limited direct binding validation\",\n      \"pmids\": [\"40534096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Recombinant Lgals9 protein promotes macrophage polarization toward the M2b phenotype in vitro, as demonstrated in the context of mouse cardiac transplantation.\",\n      \"method\": \"Flow cytometry, ELISA, RT-qPCR, Western blotting, recombinant protein treatment of macrophages\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, recombinant protein treatment with phenotypic readout, no detailed molecular mechanism\",\n      \"pmids\": [\"39835675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In macrophages, rhamnose binds to CEACAM1 at residues V39, D40, and T101, promoting CEACAM1-LGALS9 interaction, which increases DUSP1 protein levels, inhibits p38 phosphorylation, and attenuates LPS-triggered proinflammatory cytokine expression.\",\n      \"method\": \"In silico molecular docking, in vitro macrophage stimulation assays, Western blot for p38 phosphorylation and DUSP1, LPS-induced endotoxic mouse model\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — novel protein interaction and downstream signaling identified, but direct CEACAM1-LGALS9 interaction validation limited, single lab\",\n      \"pmids\": [\"40708539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"LGALS9-positive corneal epithelial cells interact with CD44-positive, COMP-positive corneal stromal cells via LGALS9-CD44 signaling, promoting extracellular matrix remodeling and a pro-fibrotic/pro-inflammatory network in keratoconus.\",\n      \"method\": \"scRNA-seq, intercellular communication analysis, immunofluorescence, Western blot\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — receptor-ligand interaction inferred from scRNA-seq with immunofluorescence validation, no direct binding experiment\",\n      \"pmids\": [\"41022233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"miR-491-5p targets and inhibits LGALS9 expression in gastric cancer cells, and LGALS9 knockout reverses T cell immunosuppression and enhances cytotoxic T cell activity against gastric cancer cells.\",\n      \"method\": \"LGALS9 genetic knockout, miRNA target validation, CD8+ T cell functional assays\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — KO and miRNA targeting shown, functional immune consequence demonstrated, pathway mechanistic detail limited, single lab\",\n      \"pmids\": [\"41171621\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LGALS9/Galectin-9 is a secreted and cell-associated lectin that functions as a ligand for TIM-3 (HAVCR2) and CD47, suppressing immune responses by inhibiting dendritic cell antigen presentation and promoting immunosuppressive macrophage states; intracellularly it acts as a lysosomal inhibitor blocking autophagosome-lysosome fusion in KRAS-mutant cancer cells, binds PRDX2 in a sugar-independent manner to regulate redox state in adipocytes, and its transcription is regulated by HAND2/FOXO1 and histone acetylation, while alternative splicing of LGALS9 produces functionally distinct isoforms with differential effects on endothelial biology and immune regulation.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"Galectin-9 (LGALS9) was identified as the ligand for the Tim-3 (TIM-3) receptor on Th1 cells. Galectin-9 binding to Tim-3 induced intracellular calcium flux, cell aggregation, and apoptotic death of Th1 cells in a Tim-3-dependent manner in vitro; in vivo administration selectively depleted IFN-γ-producing cells and suppressed Th1-mediated autoimmunity.\",\n      \"method\": \"In vitro binding assays, calcium flux measurements, cell death assays with Tim-3-deficient cells; in vivo administration in autoimmune models\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (binding, calcium flux, genetic Tim-3 dependence, in vivo), foundational paper with >1600 citations replicated broadly\",\n      \"pmids\": [\"16286920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"LGALS9 encodes a novel 36-kDa tandem-repeat galectin (galectin-9) with two carbohydrate recognition domains (CRDs) linked by a ~30 amino acid peptide; the protein binds galactosides via affinity chromatography on lactose/galactose resin and is expressed primarily in peripheral blood leukocytes and lymphatic tissues.\",\n      \"method\": \"cDNA cloning, sequence analysis, recombinant protein expression in CHO cells, lactose/galactose affinity chromatography\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution of galactoside-binding activity with direct affinity purification; >200 citations\",\n      \"pmids\": [\"9045665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"A splice variant of LGALS9 (ecalectin) was identified as a T-cell-derived eosinophil chemoattractant. Recombinant ecalectin attracted eosinophils in vitro and in vivo in a dose-dependent manner but not neutrophils, lymphocytes, or monocytes, and is secreted despite lacking a hydrophobic signal peptide.\",\n      \"method\": \"cDNA isolation from T-cell expression library, recombinant protein expression in COS and insect cells, in vitro and in vivo eosinophil chemotaxis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional reconstitution in vitro and in vivo with recombinant protein, >250 citations\",\n      \"pmids\": [\"9642261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Galectin-9 induces apoptosis via the calcium-calpain-caspase-1 pathway. Gal-9-induced apoptosis of T-cell lines requires beta-galactoside binding (blocked by lactose but not sucrose), induces intracellular Ca2+ influx, and is suppressed by a pan-caspase inhibitor, a caspase-1 inhibitor (Z-YVAD-FMK), a calpain inhibitor (Z-LLY-FMK), the Ca2+ chelator BAPTA-AM, or an IP3 inhibitor; caspase-8, -9, and -10 inhibitors had no effect.\",\n      \"method\": \"Cell death assays with pharmacological inhibitors (caspase, calpain, calcium), calcium flux measurements, lactose competition\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal pharmacological dissections of the pathway, >245 citations\",\n      \"pmids\": [\"12646627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"EBV-infected NPC cells release exosomes containing galectin-9 (LGALS9); exosomal galectin-9 retains Tim-3-binding capacity and has T-cell inhibitory activity, providing a mechanism for immune escape.\",\n      \"method\": \"Differential centrifugation, immunomagnetic bead purification, Western blotting, T-cell proliferation inhibition assays with anti-Tim-3 and anti-galectin-9 blocking antibodies\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — exosome isolation with functional validation using blocking antibodies; single lab\",\n      \"pmids\": [\"17156439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Galectin-9-containing exosomes released by EBV-infected NPC cells circulate in patient plasma, are protected from proteolytic cleavage when encapsulated, retain Tim-3-binding capacity, and induce apoptosis in EBV-specific CD4+ T cells; this effect is blocked by anti-Tim-3 and anti-galectin-9 antibodies.\",\n      \"method\": \"Exosome isolation from patient plasma and xenograft mouse plasma, T-cell apoptosis assays, antibody blockade experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo detection plus functional blockade, validated in patient samples and mouse model; >355 citations\",\n      \"pmids\": [\"19005181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The Tim-3/galectin-9 signaling pathway promotes expansion of CD11b+Ly-6G+ granulocytic myeloid-derived suppressor cells (MDSCs) to suppress Th1 immunity. Transgenic overexpression of Tim-3 on T cells or overexpression of galectin-9 both increase MDSCs; loss of Tim-3 restores normal MDSC levels in Gal-9 transgenic mice, establishing genetic epistasis in this pathway.\",\n      \"method\": \"Transgenic mouse models (Tim-3 OE, Gal-9 OE), Tim-3 knockout cross, flow cytometry, tumor growth assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis confirmed by double-mutant rescue, >239 citations\",\n      \"pmids\": [\"20574007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Galectin-9 binds cell surface protein disulfide isomerase (PDI) on Th2 cells, increasing PDI retention on the plasma membrane and altering the redox environment at the cell surface; this galectin-9/PDI interaction enhances T-cell migration through extracellular matrix via β3 integrins and potentiates HIV infection of T cells.\",\n      \"method\": \"Cell surface binding assays, PDI retention measurements, T-cell migration assays, HIV infection assays; galectin-PDI interaction characterized on Th2 vs. Th1 cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — identification of PDI as a binding partner with functional consequences (migration and HIV), multiple orthogonal readouts; >200 citations\",\n      \"pmids\": [\"21670307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Tim-3 functions as an inducible human NK-cell co-receptor for galectin-9 (LGALS9) that enhances IFN-γ production. Tim-3 overexpression in NK92 cells markedly increased IFN-γ in response to soluble Gal-9 or Gal-9-expressing tumor cells; Tim-3 cross-linking activated ERK and caused IκBα degradation; Tim-3 blockade significantly decreased IFN-γ production.\",\n      \"method\": \"NK cell line overexpression, primary NK cell assays with blocking antibodies, Tim-3 cross-linking, Western blotting (ERK, IκBα), IFN-γ ELISA\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional gain-of-function and antibody blockade with defined signaling readouts; >315 citations\",\n      \"pmids\": [\"22323453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In HBV-associated hepatocellular carcinoma (HCC), galectin-9 is expressed at highest levels on Kupffer cells in tumor islets; IFN-γ from tumor-infiltrating T cells stimulates galectin-9 expression on antigen-presenting cells; the Tim-3/galectin-9 pathway drives T-cell replicative senescence; blockade of this pathway restores T-cell proliferation and effector cytokine production.\",\n      \"method\": \"Immunofluorescence, flow cytometry, IFN-γ stimulation assays, Tim-3/galectin-9 pathway blockade with antibodies, T-cell functional assays\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, functional rescue by pathway blockade, >414 citations\",\n      \"pmids\": [\"22505239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Endothelial cells express five LGALS9 splice variants (including two novel ones), with splicing confined to exons 5, 6, and 10. The dominant variant galectin-9Δ5, when overexpressed intracellularly, slightly increased endothelial proliferation; recombinant galectin-9Δ5 dose-dependently inhibited endothelial proliferation and migration and had a small inhibitory effect on angiogenesis in vivo.\",\n      \"method\": \"RT-PCR splice variant identification, HMEC transfection, recombinant protein treatment, proliferation and migration assays, in vivo angiogenesis model\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional assays with recombinant protein and overexpression, but context-dependent results; single lab\",\n      \"pmids\": [\"24333696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LGALS9 D5 isoform (galectin-9Δ5) expressed in mouse and human decidua suppresses IFN-γ production by decidual natural killer cells; Lgals9 splice variant expression is differentially regulated during gestation; decreased Lgals9 D5/10 expression is associated with spontaneous abortion.\",\n      \"method\": \"Real-time PCR, immunohistochemistry, mouse gestation model, decidual NK cell functional assays\",\n      \"journal\": \"Biology of reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — functional suppression assay with specific isoform; single lab\",\n      \"pmids\": [\"23242525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Recombinant LGALS9 (rLGALS9) is selectively cytotoxic to KRAS-mutant colorectal cancer cells. Upon treatment, rLGALS9 internalizes via early and late endosomes, accumulates in lysosomes, and acts as a lysosomal inhibitor blocking autophagosome-lysosome fusion, leading to autophagosome accumulation, lysosomal swelling, and cell death ('frustrated autophagy'). This activity depends on elevated basal autophagic flux in KRAS-mutant cells and does not occur in BRAF-mutant CRC.\",\n      \"method\": \"Confocal microscopy (endosomal/lysosomal trafficking), autophagy flux assays, cell death assays in isogenic KRAS/BRAF mutant panels, recombinant protein treatment\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — imaging-based mechanistic dissection with defined genetic context and multiple readouts; single lab\",\n      \"pmids\": [\"26086204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIM-3 and galectin-9 (LGALS9) form an autocrine stimulatory loop in human acute myeloid leukemia stem cells (LSCs). TIM-3 is expressed on LSCs but not normal HSCs; Gal-9/TIM-3 signaling co-activates NF-κB and β-catenin pathways to drive LSC self-renewal; neutralization of Gal-9 inhibited xenogeneic reconstitution of human AML in mice.\",\n      \"method\": \"Flow cytometry, AML xenograft models, neutralizing antibody experiments, NF-κB and β-catenin pathway analysis, serum Gal-9 ELISA\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, in vivo validation, defined downstream signaling; >228 citations\",\n      \"pmids\": [\"26279267\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Galectin-9 (LGALS9) is an endogenous ligand for the innate immune receptor Dectin-1 on macrophages in pancreatic ductal adenocarcinoma (PDA). Dectin-1 ligation by galectin-9 drives tolerogenic macrophage programming and adaptive immune suppression; deletion of Clec7a (Dectin-1) or blockade of its downstream signaling was protective against PDA progression.\",\n      \"method\": \"Ligand-receptor binding assays (mouse and human PDA), Clec7a-knockout mouse models, macrophage polarization assays, CD4+/CD8+ T-cell functional rescue experiments\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — identification of novel receptor-ligand pair with genetic and functional validation in vivo; >307 citations\",\n      \"pmids\": [\"28394331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In AML cells, latrophilin-1 activation drives a PKC- and mTOR-dependent pathway that increases translation and exocytosis of both TIM-3 and galectin-9. TIM-3 participates in galectin-9 secretion and is also released as soluble TIM-3; soluble TIM-3 prevents IL-2 secretion; galectin-9 impairs NK-cell anti-cancer activity.\",\n      \"method\": \"Latrophilin-1 activation, pharmacological inhibition of PKC/mTOR, Western blotting, ELISA, ex vivo validation with primary AML patient samples\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway dissection with inhibitors, validated in primary patient samples; single lab\",\n      \"pmids\": [\"28750861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GBM-derived exosomal LGALS9 in cerebrospinal fluid binds TIM-3 on dendritic cells, inhibiting antigen recognition, processing, and presentation, thereby suppressing cytotoxic T-cell-mediated antitumor immunity; blocking exosomal LGALS9 secretion restored durable DC tumor-antigen-presenting activity and antitumor immunity in mice.\",\n      \"method\": \"CSF exosome proteomics, DC functional assays, TIM-3 binding assays, exosomal LGALS9 knockdown in vivo mouse model, T-cell cytotoxicity assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic in vitro and in vivo validation with specific knockdown; single lab\",\n      \"pmids\": [\"33093453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Galectin-9 (LGALS9) interacts directly with PD-1 in addition to TIM-3. PD-1 binding to galectin-9 attenuates Gal-9/TIM-3-induced T-cell death, thereby promoting persistence of PD-1+TIM-3+ exhausted T cells. Gal-9 expression and secretion are induced by IFN-β and IFN-γ.\",\n      \"method\": \"Co-IP and direct binding assays (PD-1 and galectin-9), T-cell death assays with PD-1-expressing and PD-1-deficient cells, IFN stimulation experiments, anti-Gal-9 therapy in tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding of new receptor (PD-1) confirmed, mechanistic rescue experiment, multiple functional readouts; >509 citations\",\n      \"pmids\": [\"33547304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Lgals9 deficiency in mice protected against diet-induced obesity, associated with reduced epididymal and mesenteric fat and improved glucose tolerance. Bone marrow transplant experiments demonstrated the effect is non-hematopoietic cell-intrinsic. Gal-9 physically binds peroxiredoxin-2 (PRDX2) in a sugar-chain-independent manner; Gal-9 knockdown in 3T3-L1 adipocytes shifts PRDX2 from its oxidized dimer to reduced monomer form under H2O2-induced oxidative stress.\",\n      \"method\": \"Lgals9 knockout mice, HFHS diet model, bone marrow transplantation, nanoLC-MS/MS, co-immunoprecipitation, pull-down assay, PRDX2 redox state analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS identification of PRDX2 binding confirmed by Co-IP and pull-down with functional redox readout; single lab\",\n      \"pmids\": [\"33727589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LGALS9 transcription in human endometrial stromal cells is upregulated by the transcription factor HAND2 and downregulated by FOXO1. Phosphorylation of FOXO1 prevents its DNA binding and thus relieves FOXO1-mediated suppression of LGALS9 transcription; steroid hormones regulate LGALS9 expression through modulation of HAND2 expression and FOXO1 phosphorylation status.\",\n      \"method\": \"Luciferase reporter assays for LGALS9 promoter activity, HAND2/FOXO1 overexpression and knockdown, steroid hormone treatment, RT-qPCR, FOXO1 phosphorylation analysis\",\n      \"journal\": \"Molecular human reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay with transcription factor identity established, phosphorylation mechanism defined; single lab\",\n      \"pmids\": [\"34581822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Histone H3K9 and H3K14 acetylation at the LGALS9 promoter correlates with and regulates LGALS9 mRNA levels in cervical cancer cells; CpG methylation of the LGALS9 promoter does not explain differences in expression between tumoral and non-tumoral cells.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for H3K9ac and H3K14ac, bisulfite sequencing for CpG methylation, RT-PCR for splice variant identification\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP establishes direct epigenetic mark at promoter linked to expression; single lab\",\n      \"pmids\": [\"32902187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LGALS9 promotes inflammation in osteoarthritis by activating JNK and ERK1/2 signaling pathways in chondrocytes; LGALS9 knockdown (RNAi and lentivirus) attenuated inflammatory responses in vitro and in vivo OA models.\",\n      \"method\": \"RNAi knockdown, lentiviral overexpression/knockdown, in vitro and in vivo OA models, qRT-PCR, Western blotting for p-JNK and p-ERK1/2, immunofluorescence, safranin staining\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function and gain-of-function with defined signaling pathway readouts in vivo and in vitro; single lab\",\n      \"pmids\": [\"39278441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Macrophage-derived LGALS9 interacts with the receptor P4HB (beta-subunit of prolyl 4-hydroxylase) on gastric cancer epithelial cells, activating P4HB to enhance tumor cell proliferation, epithelial-mesenchymal transition, and lipid metabolism; pharmacological P4HB inhibition reversed these effects.\",\n      \"method\": \"Single-cell RNA sequencing, ligand-receptor interaction analysis, functional proliferation and EMT assays, pharmacological inhibition of P4HB\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — receptor-ligand interaction inferred from scRNA-seq with limited biochemical validation; single lab, no replication\",\n      \"pmids\": [\"40534096\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In early-stage endometrial cancer, tumor cell CD47 stimulates macrophage HCK kinase, driving macrophage secretion of LGALS9, IL-10, and TGF-β1; macrophage-derived LGALS9 in turn signals back through CD47 on tumor cells to reinforce proliferation, establishing a CD47–HCK–LGALS9 positive feedback loop. ERRγ was identified as an upstream transcriptional regulator of CD47 suppressed by progesterone.\",\n      \"method\": \"scRNA-seq, spatial transcriptomics, multiplex immunofluorescence, CCK-8/flow cytometry proliferation assays, GST pull-down mass spectrometry, CUT&Tag, organoid-macrophage co-culture, CD47 inhibition/overexpression\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-modal validation including GST pull-down, organoid model, and CUT&Tag; single lab\",\n      \"pmids\": [\"41437376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Recombinant Lgals9 promotes macrophage polarization toward the M2b phenotype in a cardiac transplant context at appropriate concentrations, as validated by flow cytometry and ELISA.\",\n      \"method\": \"Single-cell RNA sequencing, RT-qPCR, Western blotting, flow cytometry, ELISA, recombinant Lgals9 treatment of macrophages in vitro\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single in vitro recombinant protein treatment experiment; single lab, no mechanistic pathway identified\",\n      \"pmids\": [\"39835675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Intratumoral cell-associated (non-secreted) LGALS9 suppresses cytotoxic T lymphocyte activation in nasopharyngeal carcinoma via a macroautophagy-dependent mechanism.\",\n      \"method\": \"LGALS9 overexpression in NPC cell lines, autophagy manipulation, CTL activation assays (commentary/brief report citing Kam et al. experimental data)\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — commentary describing experimental findings from cited primary paper; limited direct experimental detail in abstract\",\n      \"pmids\": [\"40698512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Rhamnose binds to CEACAM1 at sites V39, D40, and T101, promoting CEACAM1–LGALS9 interaction in macrophages, which increases DUSP1 protein levels, inhibits p38 phosphorylation, and attenuates LPS-induced proinflammatory cytokine expression.\",\n      \"method\": \"LPS-induced endotoxic mouse model, molecular docking, in vitro macrophage binding assays, CEACAM1-LGALS9 co-immunoprecipitation, Western blotting for DUSP1 and p-p38, cytokine ELISA\",\n      \"journal\": \"Acta biochimica et biophysica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP confirmed CEACAM1-LGALS9 interaction with defined downstream signaling in vitro and in vivo; single lab\",\n      \"pmids\": [\"40708539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In keratoconus, LGALS9-positive corneal epithelial cells interact with COMP-positive and CD44-positive stromal cells through LGALS9-CD44 and thrombospondin signaling pathways, promoting extracellular matrix remodeling and a pro-fibrotic/pro-inflammatory network; LGALS9 upregulation in keratoconus corneal epithelium was validated by immunofluorescence and Western blot.\",\n      \"method\": \"Single-cell RNA sequencing, intercellular communication analysis, immunofluorescence, Western blotting in patient keratoconus vs. control corneal tissue\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — interaction inferred from scRNA-seq with validation limited to expression-level confirmation; single lab\",\n      \"pmids\": [\"41022233\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LGALS9 encodes galectin-9, a secreted tandem-repeat β-galactoside-binding lectin that functions as the canonical ligand for the TIM-3 immune checkpoint receptor, inducing Th1 cell death via a Ca2+-calpain-caspase-1 cascade and suppressing antitumor immunity through exosomal delivery to dendritic cells and direct TIM-3 signaling; it additionally binds PD-1 (attenuating Gal-9/TIM-3 killing to sustain exhausted T cells), Dectin-1 on macrophages (driving tolerogenic programming in pancreatic cancer), and cell-surface PDI (altering redox status and β3-integrin-mediated migration on Th2 cells), while intracellularly acting as a lysosomal inhibitor that blocks autophagosome-lysosome fusion to trigger 'frustrated autophagy' selectively in KRAS-mutant cancer cells, and its transcription is regulated by HAND2 (activating) and FOXO1 (repressing) with histone H3K9/H3K14 acetylation as an additional epigenetic control layer.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LGALS9 (Galectin-9) is a β-galactoside-binding lectin that functions as a secreted and cell-surface immunomodulatory ligand, shaping innate and adaptive immune responses through engagement of multiple receptors on immune and epithelial cells. Exosomal or myeloid-derived LGALS9 binds TIM-3 on dendritic cells to suppress antigen presentation and anti-tumor T cell immunity [PMID:33093453], binds CD47 on cancer cells to promote an immunosuppressive macrophage-tumor feedback loop [PMID:41437376], and drives macrophage-dependent inflammation in lupus through mechanisms independent of T/B cell subset alterations [PMID:29481735]. Intracellularly, recombinant LGALS9 traffics through endosomes to lysosomes in KRAS-mutant colorectal cancer cells, where it blocks autophagosome–lysosome fusion and induces autophagic cell death [PMID:26086204]; it also binds peroxiredoxin-2 (PRDX2) in a sugar-independent manner to regulate redox balance in adipocytes [PMID:33727589]. Alternative splicing generates functionally distinct isoforms that differentially regulate endothelial cell proliferation and migration and modulate NK cell interferon-γ production at the fetal–maternal interface [PMID:24333696, PMID:23242525].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstration that LGALS9 undergoes alternative splicing in endothelial cells to produce functionally distinct isoforms established that a single gene generates variants with opposing effects on cell proliferation and angiogenesis.\",\n      \"evidence\": \"RT-PCR splice variant mapping and recombinant protein/transfection assays in HMECs and HUVECs with in vivo angiogenesis model\",\n      \"pmids\": [\"24333696\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which extracellular vs. intracellular isoform action diverges is unresolved\", \"Splice variant-specific receptor engagement not tested\", \"Structural basis for isoform functional differences unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification that the LGALS9 Δ5 isoform suppresses decidual NK cell IFN-γ production linked LGALS9 splicing to fetal–maternal immune tolerance, raising the question of isoform-specific immune regulation.\",\n      \"evidence\": \"Real-time PCR and immunohistochemistry in mouse gestational tissues, NK cell functional assay with recombinant Δ5 isoform\",\n      \"pmids\": [\"23242525\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Functional assay limited to a single readout (IFN-γ)\", \"Receptor on NK cells mediating suppression not identified\", \"Causal role in abortion model not demonstrated by rescue\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that recombinant LGALS9 traffics to lysosomes and blocks autophagosome–lysosome fusion in KRAS-mutant CRC cells revealed a novel intracellular anti-tumor mechanism distinct from its extracellular lectin functions.\",\n      \"evidence\": \"Live-cell endosomal tracking, autophagy flux and lysosomal integrity assays in KRAS- vs. BRAF-mutant CRC lines\",\n      \"pmids\": [\"26086204\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct lysosomal target of LGALS9 not identified\", \"Whether endogenous intracellular LGALS9 recapitulates this effect is unknown\", \"In vivo anti-tumor efficacy of this mechanism not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Lgals9 knockout protection against pristane-induced lupus, mediated through macrophage activation rather than lymphocyte subset changes, established Gal-9 as a macrophage-dependent driver of autoimmune inflammation in vivo.\",\n      \"evidence\": \"Lgals9 KO mouse with pristane-induced lupus, flow cytometry of immune subsets, peritoneal macrophage cytokine profiling\",\n      \"pmids\": [\"29481735\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific macrophage receptor for Gal-9 in this context not determined\", \"Downstream signaling pathway in macrophages not delineated\", \"Whether TIM-3 mediates this effect was not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstration that glioblastoma exosomal LGALS9 binds TIM-3 on dendritic cells to suppress antigen presentation and anti-tumor immunity identified the TIM-3–LGALS9 axis as a targetable immune evasion mechanism in the CNS.\",\n      \"evidence\": \"Proteomic analysis of CSF exosomes, TIM-3 binding assays, DC functional assays, in vivo tumor model with LGALS9 blockade\",\n      \"pmids\": [\"33093453\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether other galectins on exosomes contribute was not excluded\", \"Structural details of LGALS9–TIM-3 interaction not resolved\", \"Applicability beyond glioblastoma models untested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of PRDX2 as a sugar-independent binding partner of Gal-9 that regulates adipocyte redox state, coupled with obesity resistance in Lgals9 KO mice, revealed an intracellular lectin-independent metabolic function.\",\n      \"evidence\": \"nanoLC-MS/MS, Co-IP, pull-down, RNAi in 3T3-L1 adipocytes, Lgals9 KO mice on high-fat diet\",\n      \"pmids\": [\"33727589\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding interface between Gal-9 and PRDX2 not mapped\", \"Whether the metabolic phenotype is PRDX2-dependent was not tested\", \"Mechanism linking PRDX2 redox regulation to obesity resistance unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstration that HAND2 activates and phospho-FOXO1 relieves repression of LGALS9 transcription provided a molecular mechanism for steroid hormone-driven control of LGALS9 expression in the endometrium.\",\n      \"evidence\": \"Luciferase reporter assays, transcription factor overexpression/knockdown, phospho-FOXO1 analysis in endometrial stromal cells\",\n      \"pmids\": [\"34581822\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct HAND2 binding site on LGALS9 promoter not mapped by ChIP\", \"Whether this regulation extends beyond endometrial cells unknown\", \"Functional consequence of HAND2/FOXO1-driven LGALS9 regulation for decidualization not shown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery that macrophage-derived LGALS9 binds CD47 on endometrial cancer cells, establishing a CD47–HCK–LGALS9 positive feedback loop driving immunosuppression, identified a second major immune checkpoint receptor for LGALS9 beyond TIM-3.\",\n      \"evidence\": \"GST pull-down MS, molecular docking, scRNA-seq, spatial transcriptomics, CUT&Tag, organoid-macrophage co-culture\",\n      \"pmids\": [\"41437376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biophysical validation of LGALS9–CD47 binding affinity not provided\", \"Whether TIM-3 and CD47 are engaged simultaneously by LGALS9 is unknown\", \"Generalizability of the feedback loop to other cancer types untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The receptor hierarchy and context-dependent selectivity of LGALS9 for its multiple receptors (TIM-3, CD47, CD44, CEACAM1) remains unresolved, as does the structural basis for its sugar-independent intracellular interactions and the in vivo relevance of its lysosomal inhibitory activity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of LGALS9 bound to any of its identified receptors\", \"Relative contributions of TIM-3 vs. CD47 in tumor immune evasion not compared in a single system\", \"In vivo validation of the autophagy-blocking mechanism in KRAS-mutant tumors is lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 9, 10]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 4, 9, 14]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"HAVCR2\",\n      \"CD47\",\n      \"PRDX2\",\n      \"CEACAM1\",\n      \"HAND2\",\n      \"FOXO1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Galectin-9 is a tandem-repeat β-galactoside-binding lectin that functions as a pleiotropic immunomodulator, shaping adaptive and innate immunity through engagement of multiple cell-surface receptors and an intracellular role in autophagy regulation. Secreted galectin-9 is the canonical ligand for TIM-3, triggering Th1 cell apoptosis via a Ca²⁺–calpain–caspase-1 cascade [PMID:16286920, PMID:12646627], and also binds PD-1, where PD-1 co-engagement attenuates TIM-3-mediated killing and sustains exhausted T-cell persistence [PMID:33547304]; additionally, it ligates Dectin-1 on macrophages to drive tolerogenic programming in pancreatic cancer [PMID:28394331], and binds cell-surface protein disulfide isomerase to modulate Th2 migration and redox status [PMID:21670307]. Tumor-derived exosomal galectin-9 suppresses antitumor immunity by inhibiting dendritic-cell antigen presentation [PMID:33093453, PMID:19005181], while an autocrine TIM-3/galectin-9 loop co-activates NF-κB and β-catenin to promote leukemia stem-cell self-renewal [PMID:26279267]; intracellularly, galectin-9 acts as a lysosomal inhibitor that blocks autophagosome–lysosome fusion, selectively killing KRAS-mutant colorectal cancer cells through frustrated autophagy [PMID:26086204].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Molecular cloning established that LGALS9 encodes a tandem-repeat galectin with two carbohydrate-recognition domains capable of β-galactoside binding, defining the protein's fundamental biochemical identity.\",\n      \"evidence\": \"cDNA cloning, recombinant expression in CHO cells, lactose/galactose affinity chromatography\",\n      \"pmids\": [\"9045665\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure of full-length tandem-repeat protein not resolved\", \"Relative affinities of N- and C-terminal CRDs for complex glycans not defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Discovery that a galectin-9 splice variant (ecalectin) acts as a selective eosinophil chemoattractant revealed that galectin-9 has direct leukocyte-recruiting activity independent of its later-identified Tim-3 pathway.\",\n      \"evidence\": \"Recombinant ecalectin in COS/insect cells, in vitro and in vivo eosinophil chemotaxis assays\",\n      \"pmids\": [\"9642261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating eosinophil chemotaxis not identified\", \"Mechanism of non-classical secretion not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Pharmacological dissection showed galectin-9 induces T-cell apoptosis through a Ca²⁺–calpain–caspase-1 pathway, distinguishing this death mechanism from classical caspase-8/9-dependent apoptosis.\",\n      \"evidence\": \"T-cell death assays with selective caspase, calpain, and calcium inhibitors; lactose competition\",\n      \"pmids\": [\"12646627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct calpain substrates downstream of galectin-9 not identified\", \"Tim-3 dependence not yet tested (predates Tim-3 identification as the receptor)\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of galectin-9 as the endogenous ligand for TIM-3 on Th1 cells unified the eosinophil/apoptosis activities under a receptor-mediated framework and established the TIM-3/galectin-9 axis as an immune checkpoint.\",\n      \"evidence\": \"In vitro binding, calcium flux, Tim-3-deficient cell controls, in vivo depletion of IFN-γ+ cells in autoimmune models\",\n      \"pmids\": [\"16286920\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Tim-3 is the sole apoptosis-inducing receptor or other receptors contribute remained unclear\", \"Structural basis of galectin-9/Tim-3 interaction not determined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstration that EBV-infected tumor cells package galectin-9 into exosomes that retain Tim-3-binding and T-cell-inhibitory capacity revealed a paracrine immune-evasion mechanism, later confirmed in patient plasma and extended to glioblastoma-derived CSF exosomes.\",\n      \"evidence\": \"Exosome purification from NPC cell lines and patient plasma, antibody blockade, DC/T-cell functional assays, in vivo knockdown (GBM model)\",\n      \"pmids\": [\"17156439\", \"19005181\", \"33093453\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sorting mechanism for galectin-9 loading into exosomes not defined\", \"Relative contribution of exosomal versus soluble galectin-9 to immune suppression in vivo not quantified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Genetic epistasis experiments using Tim-3-overexpressing and Gal-9-overexpressing transgenic mice showed that the Tim-3/galectin-9 axis expands granulocytic MDSCs, broadening the pathway's immunosuppressive scope beyond direct T-cell killing.\",\n      \"evidence\": \"Tim-3-OE × Gal-9-OE double-transgenic and Tim-3-KO rescue crosses, flow cytometry, tumor models\",\n      \"pmids\": [\"20574007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling cascade from Tim-3 in myeloid cells driving MDSC expansion not mapped\", \"Whether MDSC expansion is cell-intrinsic or indirect not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of cell-surface protein disulfide isomerase (PDI) as a galectin-9 receptor on Th2 cells revealed a Tim-3-independent pathway linking galectin-9 to redox regulation, β3-integrin-mediated migration, and HIV entry.\",\n      \"evidence\": \"Surface binding assays, PDI retention measurements, migration and HIV infection assays comparing Th1/Th2 cells\",\n      \"pmids\": [\"21670307\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Glycan moieties on PDI mediating galectin-9 binding not characterized\", \"Relative physiological importance of PDI versus Tim-3 pathway on Th2 cells unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Tim-3 was shown to function as a co-stimulatory receptor for galectin-9 on NK cells (activating ERK and NF-κB to enhance IFN-γ), contrasting with its pro-apoptotic role on Th1 cells and demonstrating cell-type-specific signaling outcomes.\",\n      \"evidence\": \"NK92 overexpression, primary NK blocking antibody experiments, Western blotting for ERK and IκBα\",\n      \"pmids\": [\"22323453\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for opposing outcomes in T cells versus NK cells not explained\", \"Adaptor proteins downstream of Tim-3 in NK cells not identified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Two discoveries expanded galectin-9's functional repertoire: an autocrine TIM-3/Gal-9 loop co-activating NF-κB and β-catenin for AML LSC self-renewal, and an intracellular role as a lysosomal inhibitor that blocks autophagosome–lysosome fusion to selectively kill KRAS-mutant CRC cells.\",\n      \"evidence\": \"AML xenograft models with neutralizing antibody, NF-κB/β-catenin pathway analysis; confocal endosomal/lysosomal trafficking, autophagy flux assays in isogenic KRAS/BRAF panels\",\n      \"pmids\": [\"26279267\", \"26086204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct lysosomal target of galectin-9 not identified\", \"Whether intracellular Gal-9 and secreted Gal-9 have distinct structural states not known\", \"Mechanism by which KRAS dependency confers selective sensitivity not fully resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Galectin-9 was identified as an endogenous ligand for the innate receptor Dectin-1 on macrophages, revealing a Tim-3-independent immunosuppressive axis in pancreatic cancer where Dectin-1 ligation drives tolerogenic macrophage polarization.\",\n      \"evidence\": \"Ligand-receptor binding assays, Clec7a-knockout mice, macrophage polarization and T-cell rescue experiments in PDA models\",\n      \"pmids\": [\"28394331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Glycan determinants distinguishing Gal-9 binding to Dectin-1 versus Tim-3 not mapped\", \"Whether Dectin-1/Gal-9 signaling operates in non-pancreatic tumors not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that galectin-9 directly binds PD-1 and that PD-1 co-engagement attenuates Tim-3-mediated T-cell death fundamentally reframed the checkpoint: Gal-9 is a multi-receptor hub where PD-1 acts as a protective co-receptor sustaining exhausted T cells.\",\n      \"evidence\": \"Co-IP and direct binding assays, PD-1-deficient T-cell death comparisons, IFN-β/γ induction experiments, anti-Gal-9 tumor therapy\",\n      \"pmids\": [\"33547304\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether PD-L1 and Gal-9 compete for PD-1 binding not determined\", \"Crystal structure of PD-1/Gal-9 complex not available\", \"Therapeutic implications of dual PD-1 + Gal-9 blockade versus single blockade not fully characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Transcriptional regulation of LGALS9 was delineated: HAND2 activates and FOXO1 represses the LGALS9 promoter in endometrial stromal cells, with FOXO1 phosphorylation relieving suppression; separately, histone H3K9/H3K14 acetylation at the promoter controls expression in cervical cancer cells.\",\n      \"evidence\": \"Luciferase reporter assays, HAND2/FOXO1 overexpression/knockdown, ChIP for H3K9ac/H3K14ac, bisulfite sequencing\",\n      \"pmids\": [\"34581822\", \"32902187\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether HAND2/FOXO1 regulation operates outside endometrial tissue not tested\", \"Identity of histone acetyltransferases/deacetylases acting at the LGALS9 promoter not determined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Recent studies extended galectin-9's receptor repertoire to CEACAM1 on macrophages (increasing DUSP1 and inhibiting p38 to suppress inflammation) and identified additional signaling contexts including JNK/ERK activation in osteoarthritis chondrocytes and a CD47–HCK–LGALS9 feedback loop in endometrial cancer.\",\n      \"evidence\": \"Co-IP for CEACAM1–LGALS9, endotoxemia mouse model; RNAi/lentiviral knockdown in OA models; scRNA-seq, organoid–macrophage co-culture, CUT&Tag in endometrial cancer\",\n      \"pmids\": [\"40708539\", \"39278441\", \"41437376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical binding of galectin-9 to CEACAM1 versus indirect association not fully distinguished\", \"Relative contributions of multiple galectin-9 receptors in any single disease context not integrated\", \"Whether CD47 is a direct galectin-9 receptor or signals indirectly not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of galectin-9's selective engagement with its expanding receptor repertoire (TIM-3, PD-1, Dectin-1, PDI, CEACAM1), the molecular identity of its intracellular lysosomal target mediating autophagy blockade, and the determinants that switch TIM-3/Gal-9 signaling between pro-apoptotic (T cells) and pro-survival (AML LSCs, NK cells) outcomes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure for any galectin-9/receptor complex\", \"Intracellular lysosomal target not identified\", \"Cell-type-specific adaptor proteins downstream of TIM-3 not mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 5, 14, 17]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 7, 14]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 13, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 2, 5, 17]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4, 5, 16]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [12, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 3, 6, 8, 9, 14, 17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 3, 5]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 13, 17, 21]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [12, 25]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 5, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"HAVCR2\",\n      \"PDCD1\",\n      \"CLEC7A\",\n      \"P4HB\",\n      \"CEACAM1\",\n      \"PRDX2\",\n      \"CD44\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}